Kgn Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 14 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
About Kgn Bio-Tech
Kgn Bio-Tech Limited (KBL) is a Public Limited Indian Non-Government Company incorporated in India on 06 April 2010 and has a history of 14 years and nine months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Ismail Memon, Babulal Hirani, Janki Vaishya, and One other member serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U01400MH2010PLC201743
-
Company No.
201743
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
06 Apr 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Kgn Bio-Tech?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ismail Memon
|
Director | 10-Aug-2010 | Current |
|
Babulal Hirani
|
Director | 06-Apr-2010 | Current |
|
Janki Vaishya
|
Director | 13-Nov-2018 | Current |
|
Mohsin Memon
|
Additional Director | 15-Jan-2014 | Current |
Financial Performance of Kgn Bio-Tech.
Kgn Bio-Tech Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kgn Bio-Tech?
In 2017, Kgn Bio-Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Kgn Industries LimitedIsmail Memon, Babulal Hirani and 1 more are mutual person
-
Kgn Enterprises LimitedIsmail Memon, Babulal Hirani and 1 more are mutual person
-
Kgn Green Limited
Ismail Memon, Babulal Hirani and 1 more are mutual person
-
Kgn Proteins Limited
Ismail Memon, Babulal Hirani and 2 more are mutual person
-
Kgn Foundation
Ismail Memon is a mutual person
-
Kgn Institute Of Management
Ismail Memon is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kgn Bio-Tech?
Unlock and access historical data on people associated with Kgn Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kgn Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kgn Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
